ZURA earnings analysis
What we found in ZURA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided excerpt is limited to Part II and does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A; therefore, revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. Controls were deemed effective as of June 30, 2026, with no material internal-control changes during the quarter. Risk factors were unchanged from the 2025 Annual Report, while no quantitative guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Effective disclosure controls
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
- No material control changes
- The company reported no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
- No insider trading arrangements
- During the six months ended June 30, 2026, none of the company’s directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Clinical-stage risk profile unchanged
- The company states that the risks in its 2025 Annual Report remain applicable and that there have been no material changes in those risk factors. It also warns that additional risks not currently known or deemed immaterial could materially adversely affect the business, financial condition, or future results.
- Potential litigation exposure
- Although management reports no material litigation currently, it notes that litigation can create defense and settlement costs, divert management resources, and cause reputational harm, regardless of outcome.
What they said about what is next.
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. Management states that there have been no material changes to the risk factors in the 2025 Annual Report, but provides no updated operating guidance.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Zura Bio Limited reported a significant increase in operational losses for Q4 2026, with a net loss of $24.2 million, compared to $17.4 million in the same period last year—representing a 39% increase. The company's…
- 10-K · March 19, 2026
- Zura is a clinical-stage biotech focused on immune-mediated diseases, having in‑licensed three clinical-stage product candidates and advancing a bispecific IL‑17A/BAFF antibody (tibulizumab) in two Phase 2 trials. The…
- 10-Q · November 13, 2025
- Zura reported a quarterly net loss per share of $0.21 (three months ended Sept. 30, 2025) and a nine‑month net loss of $51.5 million, driven by a stepped-up R&D spend as the company advances Phase 2 programs. Cash…
- 10-Q · August 14, 2025
- Zura Bio reported no product revenue and a net loss of $15.993 million for the three months ended June 30, 2025 (EPS of $(0.17)), compared with a net loss of $10.329 million for Q2 2024 (EPS $(0.17)). Operating expense…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZURA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever